$38.14 1.1 2.9%
Last Trade - 7:11pm
| Market Cap | £1.75bn |
| Enterprise Value | £1.18bn |
| Revenue | £56.6m |
| Position in Universe | 1953rd / 6626 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 1.41 | 8.35 | 15.0 | 59.1 | 83.6 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. The Company is focused on creating, developing and commercializing differentiated combination cancer therapies that have the potential to cure. The Company has four clinical-stage investigational products: AB928, AB154, Zimberelimab and AB680.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | April 30, 2015 |
| Public Since | March 15, 2018 |
| No. of Shareholders: | 115 |
| No. of Employees: | 139 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | New York Stock Exchange |
| Shares in Issue | 64,923,304 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 3928 Point Eden Way, HAYWARD, 94545-3719, United States |
| Web | https://www.arcusbio.com/ |
| Phone | +1 510 6946200 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 7:11pm, shares in Arcus Biosciences Inc are trading at $38.14, giving the company a market capitalisation of £1.75bn. This share price information is delayed by 15 minutes.
Shares in Arcus Biosciences Inc are currently trading at $38.14 and the price has moved by 0.272k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arcus Biosciences Inc price has moved by 0.221k% over the past year.
Of the analysts with advisory recommendations for Arcus Biosciences Inc, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arcus Biosciences Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Arcus Biosciences Inc is scheduled to issue upcoming financial results on the following dates:
Arcus Biosciences Inc does not currently pay a dividend.
Arcus Biosciences Inc does not currently pay a dividend.
Arcus Biosciences Inc does not currently pay a dividend.
To buy shares in Arcus Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Arcus Biosciences Inc are currently trading at $38.14, giving the company a market capitalisation of £1.75bn.
Here are the trading details for Arcus Biosciences Inc:
Based on an overall assessment of its quality, value and momentum, Arcus Biosciences Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Arcus Biosciences Inc are currently priced at $38.14. At that level they are trading at 3.16% discount to the analyst consensus target price of 0.00.
Analysts covering Arcus Biosciences Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.742 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcus Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been 40.67%. At the current price of $38.14, shares in Arcus Biosciences Inc are trading at 46.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Arcus Biosciences Inc.
Arcus Biosciences Inc's management team is headed by:
Here are the top five shareholders of Arcus Biosciences Inc based on the size of their shareholding:
